I think there is certainly the immediate death that can occur. We definitely have gotten notices around immediate death, where people could not get access to an intervention that would have in fact been life-saving. That definitely has happened.
What we're more concerned about—and we're trying to figure out a system to track this maybe also internationally—is the death that will occur later on because there was a therapy that was not provided. We've had patients who say, “I need to get regular infusions, but I'm afraid to go in for an infusion, so if I skip the infusion, what's going to be the impact?” I think we definitely need to continue to track that. Unfortunately, certainly for rare diseases, we do not have a very good system to do that. That's why we are also pushing very much for data registries and the ability to do that.
Then, yes, there are the cases of immediate deaths and further disabilities as a result of it, but I think down the road we will see much more serious disabilities and progressive diseases that will also be, at the end of the day, caused by COVID and not being able to access.... I don't know exactly how we can track that, but I think we need to because if we have more waves of this, as everybody says, information is king.